Erlosiban

Drug Profile

Erlosiban

Alternative Names: OBE-001; Oxytocin antagonist - ObsEva

Latest Information Update: 29 Dec 2015

Price : $50

At a glance

  • Originator Merck Serono
  • Developer ObsEva
  • Class Oximes; Pyrrolidinones; Small molecules; Tocolytics
  • Mechanism of Action Oxytocin receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Female infertility; Preterm labour

Most Recent Events

  • 29 Dec 2015 Phase-II clinical trials in Preterm labour in Switzerland (PO) (NCT02326142)
  • 01 Sep 2015 Pharmacodynamics data from a clinical trial in Preterm labour released by ObsEva
  • 01 Mar 2015 Phase-II clinical trials in Preterm labour in United Kingdom, Belgium, Germany, Poland (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top